| Autor: |
Baez MA; Department of Medicine, University of Miami, Florida., Woo-Ming RB, Garg DC, Shapse DB, Deitch MW, Weidler DJ |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical pharmacology [J Clin Pharmacol] 1991 Apr; Vol. 31 (4), pp. 312-7. |
| DOI: |
10.1002/j.1552-4604.1991.tb03711.x |
| Abstrakt: |
This open crossover study in eight hypertensive patients defined a possible additive effect of oral guanabenz and captopril and determined a safe and effective dose range. Each group of four patients received placebo followed by ascending doses (on alternate days) of either guanabenz (2, 4, 8 mg) or captopril (6.25, 12.5, 25 mg) as initial monotherapy and were subsequently crossed over to the alternate monotherapy. Guanabenz and captopril were given concomitantly in increasing doses--the highest dose for both groups being 8 mg guanabenz/25 mg captopril. When guanabenz and captopril were given concomitantly, blood pressure decreased, both from the values during placebo administration and from the lead-in values recorded before each dose. Mean supine systolic and diastolic blood pressures after combination therapy decreased significantly (P less than .05) in a dose-related manner at most evaluations. The authors conclude that guanabenz and captopril have an additive effect when administered in combination to patients with hypertension. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text